"Diabetic Retinopathy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Descriptor ID |
D003930
|
| MeSH Number(s) |
C11.768.257 C14.907.320.382 C19.246.099.500.382
|
| Concept/Terms |
Diabetic Retinopathy- Diabetic Retinopathy
- Diabetic Retinopathies
- Retinopathies, Diabetic
- Retinopathy, Diabetic
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Retinopathy".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Retinopathy".
This graph shows the total number of publications written about "Diabetic Retinopathy" by people in this website by year, and whether "Diabetic Retinopathy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 0 | 3 |
| 2014 | 5 | 2 | 7 |
| 2015 | 2 | 0 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 6 | 0 | 6 |
| 2020 | 6 | 1 | 7 |
| 2022 | 4 | 0 | 4 |
| 2023 | 6 | 1 | 7 |
| 2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetic Retinopathy" by people in Profiles.
-
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmol Retina. 2024 Oct; 8(10):943-952.
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
-
Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study. Diabetologia. 2024 Jun; 67(6):1114-1121.
-
ASSOCIATION OF METFORMIN USE WITH RISK OF NEWLY ONSET NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEVELOPMENT. Retina. 2024 02 01; 44(2):205-213.
-
Racial Differences in Choroidal Vascularity Index in Healthy Patients: Novel Insights. Ophthalmic Surg Lasers Imaging Retina. 2024 Jan; 55(1):30-38.
-
Multidimensional sleep health and diabetic retinopathy: Systematic review and meta-analysis. Sleep Med Rev. 2024 Apr; 74:101891.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Association of Metformin and Other Diabetes Medication Use and the Development of New-Onset Dry Age-Related Macular Degeneration: A Case-Control Study. Invest Ophthalmol Vis Sci. 2023 08 01; 64(11):22.
-
Greater sleep variability is associated with higher systemic inflammation in type 2 diabetes. J Sleep Res. 2024 May; 33(3):e13989.
-
The Next-Generation Diagnostic and Therapeutic Algorithms for Diabetic Macular Edema Using Artificial Intelligence. Ophthalmic Surg Lasers Imaging Retina. 2023 04; 54(4):201-204.